UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION

In the Matters of

MOLECULIN BIOTECH, INC., and WALTER V. KLEMP,

-AND-

CNS PHARMACEUTICALS, INC., and JOHN M. CLIMACO,

Administrative Proceeding File Nos. 3-19789 and 3-19790

DIVISION OF ENFORCEMENT ANSWERING BRIEF

Pursuant to the Commission's Orders Requesting Additional Written Submissions in the matters of Moleculin Biotech, Inc. ("Moleculin") and Walter V. Klemp (Admin. Proc. File No. 3-19790), and CNS Pharmaceuticals, Inc. ("CNS") and John M. Climaco (Admin. Proc. File No. 3-19789), the Division of Enforcement files this answering brief. On May 29, 2020, the Petitioners in these cases filed notices of withdrawal for their petitions. They did not file an opening brief. Accordingly, the Division respectfully requests that the Commission dismiss their petitions and terminate these administrative proceedings.

By its attorneys,

/s/Richard M. Harper II
Richard M. Harper II
Celia Moore
Michael Vito
U.S. Securities and Exchange Commission
33 Arch Street, 24th Floor
Boston, Massachusetts 02110
(617) 573-8979 (Harper)
(617) 573-4590 (Facsimile)

CERTIFICATE OF SERVICE

I hereby certify that, on June 12, 2020, I served copies of the foregoing Division of Enforcement Answering Brief by electronic mail upon the following parties:

Counsel for Petitioners Cavas Pavri, Esq. Schiff Hardin LLP cpavri@schiffhardin.com

/s/Richard M. Harper II
Richard M. Harper II